Welcome to our dedicated page for Chronoscale Holdings Corporation SEC filings (Ticker: CHRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Chronoscale Holdings Corporation's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Chronoscale Holdings Corporation's regulatory disclosures and financial reporting.
ChronoScale Corp director William M. Clancy has filed an initial Form 3 reporting his beneficial ownership position. The filing lists him as a director but does not report any stock transactions or derivative positions, indicating this is a baseline disclosure rather than a trading event.
ChronoScale Corp director Richard N. Nottenburg has submitted a Form 3 initial statement of beneficial ownership. The Form 3 lists him as a director of ChronoScale but shows no reported transactions or share movements, with buy, sell, acquisition, and disposition counts all at zero.
ChronoScale Corp director and Chief Executive Officer Chen Ying Cenly has filed an initial Form 3, which is the required statement of beneficial ownership for new insiders. The data provided shows no reportable transactions or derivative positions, indicating this is a baseline disclosure of insider status rather than a trading event.
Ekso Bionics Holdings, Inc. reporting persons Armistice Capital, LLC and Steven Boyd amend a Schedule 13G/A to disclose beneficial ownership of 187,151 shares of Common Stock, representing 4.99% of the class as stated in Item 4. The filing identifies Armistice Capital as investment manager of the Master Fund and Mr. Boyd as its managing member. The ownership figures are presented in the filing with an as of reference to 03/31/2026 on the cover.
ChronoScale Corp (CHRN) Schedule 13G/A amendment reports that Mink Brook Partners LP and related entities held 0 shares of Common Stock as of the close of business on May 14, 2026. The filing disclaims beneficial ownership by Mink Brook Capital GP LLC and William Mueller except for any pecuniary interest.